Patient safety is the through-line that connects mainstream medical organizations, regulators, and stakeholder groups around the post-Category-2 peptide environment. Coverage on this site has tracked three threads: post-market FAERS adverse-event reports for newly approved drugs, compounding-pharmacy quality control as the bulks-list shifts, and the consumer-education push that frames safety messaging for a non-specialist audience.
April and early May 2026 produced material examples: the FDA logged a Foundayo hepatic-failure FAERS case on April 30 — surfaced publicly May 4, prompting Eli Lilly to release updated safety data citing no DILI signal across the 11,000-patient ACHIEVE+ATTAIN program. The American Medical Association ran a primer titled 'What Doctors Wish Patients Knew About Injectable Peptides.' The Partnership for Safe Medicines applauded the FDA's April 30 503B GLP-1 bulks-list proposal, citing 455+ FAERS reports for compounded semaglutide and 320+ for compounded tirzepatide, many involving multidose-vial dosing errors.
Stories here cover safety signal evaluation, advocacy messaging, and post-market surveillance. See #faers, #compounding, and #consumer-education.
Drexel University's news desk ran a May 5 Q&A on peptide popularity and safety, framed by the FDA's April Category 2 removals and the upcoming July 23–24 PCAC meeting on seven peptides for the 503A bulks list. The piece covers why peptides are surging — easier and cheaper synthesis since the 1980s genetic-engineering era, plus newer molecules like GLP-1 with broad therapeutic effects — and the safety gaps: pharmacy-to-pharmacy compounding variability, supply not keeping up with demand, and a gray-market problem that pushes patients to unverified online sources. The Q&A joins the AMA, AJMC, Pharmacy Times, MIT Technology Review, and the American Council on Science and Health pieces in the post-Category-2 consumer-education ecosystem.
Eli Lilly's Global Patient Safety team responded to the FDA's request for updated Foundayo safety information on May 4, concluding the FAERS event was 'not reasonably related to Foundayo.' The company pointed to the 11,000-participant ACHIEVE and ATTAIN program — followed for up to two years — where the liver safety profile of Foundayo was similar to placebo and active comparator medicines, with no cases of drug-induced liver injury observed and no hepatic safety signal detected. ACHIEVE-4 specifically included a thorough drug-induced liver injury (DILI) analysis with no hepatic signals, consistent with the 57% lower all-cause death rate (HR 0.43) seen versus insulin glargine in that arm.
The Partnership for Safe Medicines issued a May statement strongly supporting the FDA's April 30 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing-facility bulks list, citing 'sound science, sound law, and a clear-eyed commitment to patient safety.' The Partnership cited more than 455 adverse-event reports linked to compounded semaglutide and more than 320 tied to compounded tirzepatide — many involving dosing errors from multidose vials, some leading to hospitalization — as the safety basis. The group plans to submit a full comment to the Federal Register docket before the June 29 deadline and is encouraging other patient-safety groups to do the same.
The American Medical Association published a consumer-facing primer on April 30 framing the safety risks of unregulated injectable peptides marketed online for weight loss, recovery, muscle growth, and anti-aging. Physicians quoted in the piece urge patients to push past social-media claims and discuss intended use with a clinician, noting that many products sold under wellness branding are not FDA-approved and may carry sterility, dosing, and interaction risks. The piece joins recent coverage from STAT, Scientific American, the Washington Post, ABC News affiliates, and Columbia Doctors as mainstream medicine reacts to the post-Category-2 environment.